glp 1 agonists canada View of Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor How GLP-1 Receptor Agonists Evolved

doi:10.1503/cmaj.240768

39 It was approved by the US FDA in 2014 to treat obesity (Saxenda , Novo Nordisk, Plainsboro, NJ, USA), after first being approved as a type 2 diabetes medication (Victoza , Novo Nordisk) in 2010 (Table 1)

Some analyses from these trials showed modest reductions in inflammatory biomarkers, including high-sensitivity C-reactive protein (hs-CRP)

YX: Writing review & editing

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) enhance cardiometabolic health, leading to improved glycemic control, weight loss, and better cardiovascular risk profile [4]

Methods GLP-1 agonists included in the analysis were approved for treatment of obesity (Saxenda, Wegovy, Zepbound) and corresponding formulations that may potentially be used off-label for treatment of obesity (Mounjaro, Ozempic, Rybelsus, Victoza)